Brain Disorders & Therapy

Authentication of Transcriptomic Insights into Neurodegenerative and Psychiatric Disorders

Noah Dhakshin^* Department of Neurology, University of Melbourne, Parkville, Victoria, Australia
^*Correspondence: Noah Dhakshin, Department of Neurology, University of Melbourne, Parkville, Victoria, Australia, Email:

Received: 01-Mar-2024, Manuscript No. BDT-24-25505; Editor assigned: 04-Mar-2024, Pre QC No. BDT-24-25505 (PQ); Reviewed: 18-Mar-2024, QC No. BDT-24-25505; Revised: 25-Mar-2024, Manuscript No. BDT-24-25505 (R); Published: 01-Apr-2024, DOI: 10.35248/2168-975X.24.13.257

Description

The difficult landscape of neuroscience, the boundaries between neurodegenerative disorders like Alzheimer's and Parkinson's disease and psychiatric disorders such as depression and schizophrenia have long been perceived as distinct. However, recent advancements in transcriptomic profiling have begun to uncover unexpected commonalities that challenge these traditional distinctions. By scrutinizing the molecular signatures encoded within the brain's transcriptome, researchers are unveiling shared pathways and mechanisms underlying seemingly disparate conditions. This article delves into the intresting insights collected from brain transcriptomic profiling, highlighting the common alterations observed across various neurodegenerative and psychiatric disorders [1].

Transcriptomic profiling involves the comprehensive analysis of all RNA transcripts within a cell or tissue at a given moment. This powerful technique provides a snapshot of gene expression patterns, offering valuable insights into the molecular dynamics underlying physiological and pathological states. In the context of neurodegenerative and psychiatric disorders, transcriptomic profiling of brain tissue has emerged as a potent tool for unravelling the molecular basis of these complex conditions [2-5]. One striking revelation from transcriptomic studies is the presence of shared gene expression changes across different neurodegenerative and psychiatric disorders. For instance, alterations in genes related to synaptic function, neuroinflammation, and mitochondrial dysfunction have been consistently identified across conditions like Alzheimer's disease, schizophrenia, and bipolar disorder. This suggests that disruptions in fundamental cellular processes may constitute a common denominator underlying diverse brain disorders. Synapses, the junctions between neurons, play a pivotal role in neuronal communication and circuitry [6]. Transcriptomic analyses have revealed dysregulation of synaptic genes in various neurodegenerative and psychiatric disorders. Genes encoding synaptic proteins such as neurotransmitter receptors, synaptic scaffolding proteins, and vesicle trafficking molecules exhibit altered expression patterns, implicating synaptic dysfunction as a shared feature. These findings underscore the importance of synaptic integrity in maintaining brain health and highlight potential therapeutic targets for intervention [7-9].

Chronic neuroinflammation, characterized by the activation of microglia and astrocytes, has emerged as a common pathogenic mechanism across multiple brain disorders. Transcriptomic studies have unveiled robust alterations in genes associated with immune response pathways, indicating a state of heightened neuroinflammatory activity. Dysregulated cytokines, chemokines, and immune signaling molecules contribute to neuronal damage and disease progression, highlighting neuroinflammation as a promising target for therapeutic intervention. Mitochondria, the cellular powerhouses responsible for energy production, also play a critical role in maintaining neuronal function and survival. Transcriptomic profiling has revealed widespread alterations in genes involved in mitochondrial biogenesis, metabolism, and oxidative stress response in neurodegenerative and psychiatric disorders. Dysfunctional mitochondria contribute to oxidative damage, energy deficits, and impaired cellular resilience, exacerbating neuronal vulnerability in disease states. Targeting mitochondrial dysfunction holds potential for mitigating disease progression and restoring cellular homeostasis. While transcriptomic profiling has provided invaluable insights into the molecular landscape of brain disorders, several challenges remain. Variability in tissue sampling, data analysis techniques, and sample sizes can influence the reproducibility and interpretation of results [10]. Moreover, translating transcriptomic findings into clinically actionable strategies requires rigorous validation and integration with other data. Collaborative efforts involving multidisciplinary expertise and large-scale data sharing initiatives are essential for advancing our understanding of complex brain disorders and developing effective treatments.

Brain transcriptomic profiling represents a powerful approach for uncovering common alterations underlying neurodegenergenerative and psychiatric disorders. By elucidating shared molecular pathways, this research holds potential for identifying novel therapeutic targets and personalized treatment strategies. As we continue to resolve dificult of the brain's transcriptome, we inch closer to a comprehensive understanding of brain disorders and the development of transformative interventions.

References

1. Xia Y, Li X, Sun W. Applications of recombinant adenovirus-p53 gene therapy for cancers in the clinic in China. Curr Gene Ther. 2020;20(2):127-141.

   [Crossref] [Google Scholar]

2. Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018;18(2):171-176.

   [Crossref] [Google Scholar]

3. Gavrilenko AV, Oleinik EM. Comprehensive treatment of a patient with Buerger's disease using genetically engineered complexes VEGF-165. Angiology Vasc Surg. 2019;25(1):177-180.

   [Crossref] [Google Scholar]

4. Zhou Y, Wen H, Gu L, Fu J, Guo J, Du L. Aminoglucose-functionalized, redox-responsive polymer nanomicelles for overcoming chemoresistance in lung cancer cells. J Nanobiotechnology. 2017; 15(1):1-7.

   [Crossref] [Google Scholar]

5. Wang Y, Zhou L, Xiao M, Sun ZL, Zhang CY. Nanomedicine-based paclitaxel induced apoptotic signaling pathways in A562 leukemia cancer cells. Colloid Surf. 2017; 149:16-22.

   [Crossref] [Google Scholar]

6. Chang D, Ma Y, Xu X, Xie J, Ju S. Stimuli-responsive polymeric nanoplatforms for cancer therapy. Front Bioeng Biotechnol. 2021;9(1):707319.

   [Crossref] [Google Scholar]

7. Kashkooli FM, Soltani M, Souri M. Controlled anti-cancer drug release through advanced nano-drug delivery systems: Static and dynamic targeting strategies. J Control Release. 2020;327(1):316-349.

   [Crossref] [Google Scholar]

8. Wu W, Klockow JL, Zhang M, Lafortune F, Chang E. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacological research. 2021; 171:105780.

   [Crossref] [Google Scholar]

9. Scheltens P, Strooper B, Kivipelto M, Holstege H. Alzheimer's disease. The Lancet. 2021 Apr 24;397(10284):1577-1590.

   [Crossref] [Google Scholar]

10. Poelmans G, Buitelaar JK, Pauls DL, Franke B. A theoretical molecular network for dyslexia: integrating available genetic findings. Mol Psychiatry. 2011;16(4):365-382.

    [Crossref] [Google Scholar]